Date: 29th July, 2026

Business Activities

Main Business Activities:

  • Manufacturing of pharmaceutical products: 82.4% of turnover
  • Wholesale Trading: 17.6% of turnover

Products/Services:

  • Pharmaceutical and nutraceutical products (NIC Code 210): 100% of total turnover

Operations

Number of Locations:

  • National: 12 plants (manufacturing sites and R&D facilities) + 9 offices (4 corporate offices and 5 directly owned depots) = 21 total
  • International: None

Note: During FY 2025-26, the Generic business undertaking was transferred to Alkem Wellness Limited (effective 1 October 2025). BRSR indicators include Generic Business impact up to transfer date.

Markets Served:

  • National: 28 states and 8 Union Territories
  • International: More than 40 countries
  • Export contribution: 27.32% of total turnover

Customer Types: Pharmaceutical firms, distributors, wholesalers, pharmacy chains, hospitals, and other healthcare-related institutional customers across domestic and international markets.

Employees and Workforce

Total Workforce (including differently abled):

Employees:

  • Permanent Employees: 17,453 (Male: 16,931 - 97%, Female: 522 - 3%)
  • Other than Permanent Employees: 291 (Male: 270 - 93%, Female: 21 - 7%)
  • Total Employees: 17,744 (Male: 17,201 - 97%, Female: 543 - 3%)

Workers:

  • Permanent Workers: 1,893 (Male: 1,862 - 98%, Female: 31 - 2%)
  • Other than Permanent Workers: 3,749 (Male: 3,531 - 94%, Female: 218 - 6%)
  • Total Workers: 5,642 (Male: 5,393 - 96%, Female: 249 - 4%)

Differently Abled Workforce:

  • Employees: 3 (All male)
  • Workers: 4 (All male)

Gender Representation:

  • Board of Directors: 12 total, 2 female (17%)
  • Key Management Personnel: 3 total, 0 female (0%)

Turnover Rates (Past 3 Years):

Permanent Employees:

  • FY 2025-26: Male 21.2%, Female 21.5%, Total 21.2%
  • FY 2024-25: Male 23.2%, Female 19.9%, Total 23.1%
  • FY 2023-24: Male 27.7%, Female 25.9%, Total 27.6%

Permanent Workers:

  • FY 2025-26: Male 11.1%, Female 3.6%, Total 11.0%
  • FY 2024-25: Male 7.3%, Female 8.2%, Total 7.3%
  • FY 2023-24: Male 10.2%, Female 7.9%, Total 10.1%

Subsidiaries and Associates

List of 35 Holding/Subsidiary/Associate Companies including:

  • Ascend GmbH (Subsidiary, 100%)
  • Pharmacor Pty Ltd (Subsidiary, 100%)
  • Enzene Biosciences Limited (Subsidiary, 99.55%)
  • Cachet Pharmaceuticals Private Limited (Subsidiary, 60.63%)
  • Indchemie Health Specialities Private Limited (Subsidiary, 51%)
  • HaystackAnalytics Private Limited (Associate, 8.16%)
  • Sunsure Solarpark Twenty Two Private Limited (Associate, 21.46%)

CSR Applicability

  • CSR applicable as per section 135 of Companies Act, 2013: Yes
  • Turnover: ₹96,639.06 million
  • Net worth: ₹1,39,981.98 million

Grievance Redressal

Complaints/Grievances FY 2025-26:

  • Communities: 0 complaints
  • Investors: 0 complaints
  • Shareholders: 0 complaints
  • Employees and workers: 15 complaints (all resolved)
  • Customers: 116 complaints (all resolved)
  • Value Chain Partners: 2 complaints (all resolved)

Grievance Mechanism: Dedicated channel available for all internal and external stakeholders. Policy available at: https://admin.alkemlabs.com/uploads/WhistleBlowerPolicynew5d094b8491.pdf

Material Responsible Business Conduct Issues

20 Material Issues Identified with Risk/Opportunity Assessment:

1. Governance (Risk and Opportunity)

2. Ethics (Risk and Opportunity)

3. Risk Management (Risk)

4. Cybersecurity and Data Privacy (Risk)

5. Innovation & R&D (Opportunity)

6. Biodiversity (Risk)

7. Climate Change and GHG Emissions (Risk and Opportunity)

8. Energy (Risk and Opportunity)

9. Waste (Risk)

10. Water (Risk)

11. Human Rights (Risk)

12. Workforce & Human Capital (Opportunity)

13. Occupational Health & Safety (Risk)

14. Community Impact (Opportunity)

15. Counterfeiting of Drugs (Risk)

16. Patient Safety and Product Quality (Risk)

17. Clinical Trials (Risk)

18. Access to Medicine and Affordability (Risk)

19. Labelling and Packaging (Risk and Opportunity)

Detailed rationales, mitigation approaches, and financial implications provided for each issue.

Management Processes

Policy Coverage: Policies cover all 9 NGRBC Principles, approved by Board

Policy Availability: https://www.alkemlabs.com/investors/policies (external) and company intranet (internal)

Policy Translation: Translated into procedures

Value Chain Extension: Policies extend to value chain partners

Certifications/Standards:

  • cGMP compliance (All sites, Principles 2,9)
  • US FDA accreditations (All sites, Principles 2,9)
  • WHO accreditations (All sites, Principles 2,9)
  • MHRA (UK) approvals (All sites, Principles 2,9)
  • TGA Australia approvals (All sites, Principles 2,9)
  • ANVISA Brazil approvals (All sites, Principles 2,9)
  • MCC South Africa approvals (All sites, Principles 2,9)
  • ISO 14001 (All manufacturing facilities & R&D centre, Principle 6)
  • ISO 45001 (Principle 3)
  • ISO 50001 (Principle 6)

Commitments and Targets:

  • Climate Change: Reduce Scope 1 and Scope 2 GHG emissions by 42% by FY 2033 from FY 2023 baseline
  • Energy: Achieve 1% annual reduction in energy consumption Y-o-Y till FY 2033
  • Water Stewardship: Achieve water neutrality by FY 2030
  • Occupational Health & Safety: Increase ISO 45001 certification coverage across manufacturing facilities
  • Diversity & Inclusion: Improve gender diversity representation to 5% by FY 2027
  • Sustainable Supply Chain: Screen 90% of new suppliers on ESG criteria (10% by FY25, 35% by FY26, 70% by FY27, >90% by FY28)
  • Information Security: Progress towards ISO 27001 implementation/certification by FY26

FY 2025-26 Performance Against Targets:

  • Climate Change: Reduced Scope 1 and Scope 2 GHG emissions by 15% from previous year
  • Energy: 100% of operational units have ISO 50001 certification. Achieved 22% reduction in energy consumption from previous year
  • Water Stewardship: Initiated integrated community watershed management programmes at Ankleshwar and Daman sites
  • Occupational Health & Safety: 100% of operational units have ISO 45001 certification
  • Diversity & Inclusion: Gender diversity stands at 3.39% of women in total workforce
  • Sustainable Supply Chain: 2% of input material sourced sustainably
  • Information Security: Gap assessment against ISO 27001 certification identified. Certification to be completed by FY27

Principle-wise Performance Disclosure

PRINCIPLE 1: Ethical, Transparent and Accountable Conduct

  • Training coverage: Board (100%), KMP (100%), Employees (100%), Workers (100%)
  • No fines/penalties/settlement amounts paid in proceedings
  • Anti-corruption policy: Yes (https://admin.alkemlabs.com/uploads/AntiBriberyandAntiCorruptionABACPolicy_c0cb337502.pdf)
  • No disciplinary actions for bribery/corruption
  • No conflict of interest complaints
  • Accounts payable days: 92 days (FY25-26) vs 112 days (FY24-25)

PRINCIPLE 2: Sustainable and Safe Goods/Services

  • R&D investment in environmental/social improvements: 0.31% of total R&D
  • CAPEX investment in environmental/social improvements: 0.49% of total CAPEX
  • Sustainable sourcing procedures: Yes (2% of inputs sourced sustainably)
  • Product reclamation processes in place for plastics, hazardous waste, other waste
  • EPR applicable: Yes, aligned with Pollution Control Board requirements

PRINCIPLE 3: Employee Well-being

Well-being Measures Coverage:

  • Permanent Employees: 100% health insurance, 100% accident insurance, 3% maternity benefits, 97% paternity benefits, 13% day care facilities
  • Workers: 100% health insurance, 100% accident insurance, 2-6% maternity benefits, 94-98% paternity benefits, 22-91% day care facilities
  • Spending on well-being: 0.2% of total revenue (FY25-26) vs 0.3% (FY24-25)

Retirement Benefits:

  • PF: 100% coverage for employees and workers, deposited with authority
  • Gratuity: 100% coverage for employees and workers, deposited with authority
  • ESI: 0% employees, 4% workers, deposited with authority
  • Other: 2% employees, 0% workers, deposited with authority

Workplace Accessibility: Premises accessible to differently abled as per Rights of Persons with Disabilities Act, 2016

Equal Opportunity Policy: Yes (https://www.alkemlabs.com/pdf/AlkemLabsCodeofEthics.pdf)

Return to Work after Parental Leave: Male 100%, Female 84.3%

Grievance Mechanism: Yes for all categories of employees and workers

Union Membership: 0% of permanent employees and workers

Training: 100% coverage on safety measures, 33-100% on skill upgradation

Performance Reviews: 86-98% of employees and workers had career reviews

Health & Safety:

  • Occupational health and safety management system implemented with full coverage
  • Processes for hazard identification and worker risk reporting (STOP initiative)
  • Non-occupational medical and healthcare services available
  • Safety incidents: LTIFR 0 for employees, 0.07 for workers; No fatalities

PRINCIPLE 4: Stakeholder Responsiveness

Stakeholder Identification Process: Based on engagement nature, dependency, responsibility, influence and impact

Key Stakeholder Groups: Customers, Communities, Business Partners/Vendors/Contractors, Employees, Workers, Regulatory Authorities, Unitholders/Investors

PRINCIPLE 5: Human Rights

Human Rights Training: 71% of employees covered

Minimum Wages: 100% of permanent employees and workers paid above minimum wage

Median Remuneration:

  • Board of Directors: ₹3,74,83,338
  • KMP: ₹2,28,10,404
  • Employees: ₹2,82,276
  • Workers: ₹2,36,136

Gross Wages to Females: 4.5% of total wages (FY25-26) vs 4.3% (FY24-25)

Human Rights Focal Point: Ethics Committee established

Complaints FY 2025-26:

  • Sexual Harassment: 2 complaints (0.26% of female workforce, 1 upheld)
  • Other human rights issues: 15 complaints (workplace harassment, ethics)

PRINCIPLE 6: Environmental Protection

Energy Consumption:

  • Total energy consumption: 7,54,500 GJ (FY25-26) vs 9,71,362 GJ (FY24-25)
  • Renewable energy: 26% of total energy consumption
  • Energy intensity: 7.1 GJ per Million INR turnover

Water Management:

  • Total water withdrawal: 6,19,064 kl (FY25-26) vs 6,84,761 kl (FY24-25)
  • Total water consumption: 5,80,641 kl (FY25-26) vs 6,56,441 kl (FY24-25)
  • Water intensity: 5.5 kl per Million INR turnover
  • Zero Liquid Discharge: Implemented at 58% of manufacturing units

Air Emissions:

  • NOx: 29 MT
  • SOx: 15 MT
  • Particulate matter: 50 MT

GHG Emissions:

  • Scope 1: 19,088.7 tCO2e
  • Scope 2 (market-based): 74,116.3 tCO2e
  • Total Scope 1+2: 93,205 tCO2e
  • Emissions intensity: 0.9 tCO2e per Million INR turnover
  • Reduction target: 42% reduction by FY2033 from FY2023 baseline

Waste Management:

  • Total waste generated: 6,228 MT
  • Waste recycled/reused: 5,931 MT (95% recovery rate)
  • Waste disposed: 413 MT
  • Waste intensity: 0.1 MT per Million INR turnover

Environmental Compliance: No non-compliances or fines reported

PRINCIPLE 7: Responsible Policy Influence

Industry Affiliations: Member of 6 trade/industry associations including IDMA, IPA, Bombay Chamber of Commerce

Anti-competitive Conduct: No cases or adverse orders

PRINCIPLE 8: Inclusive Growth

Social Impact Assessments: Conducted for 3 CSR projects in Bihar and Sikkim

Community Grievance Mechanism: Structured process through CSR team and partner agencies

Local Sourcing: 27.1% from MSMEs/small producers, 84.4% from within India

Job Creation: Wages paid in rural (10.3%), semi-urban (15.0%), urban (27.0%), metropolitan (47.7%) areas

CSR in Aspirational Districts:

  • Muzaffarpur, Bihar: Home-based Palliative Care (₹44,15,224 spent)
  • Soreng, Sikkim: Project Aagaz- Health and Sanitation (₹26,23,647 spent)

Supplier Diversity Programme: Yes, focusing on women-owned, SME, social, minority-owned, and disability-owned enterprises

CSR Beneficiaries:

  • Health: 2,31,947 persons (100% vulnerable/marginalized)
  • Environment & Sustainability: 23,594 persons (100% vulnerable/marginalized)
  • Integrated Village Development: 6,12,083 persons (100% vulnerable/marginalized)

PRINCIPLE 9: Responsible Consumer Engagement

Consumer Complaint Mechanisms: Structured process including pharmacovigilance system

  • ADR Reporting Toll-Free Number: 1800-22-99-10
  • Online ADR form: https://www.alkemlabs.com/pdf/adverse/Alkem%20ADR%20Reporting%20Form.pdf

Product Information: 100% of products carry safe and responsible usage information

Consumer Complaints: 116 pharmacovigilance reports (all resolved)

Product Recalls: 36 voluntary recalls (OOS and market complaints), 8 forced recalls (OOS and NSQ)

Cybersecurity Policy: Yes (Corporate Information Technology Policy)

Data Privacy Policy: Yes (https://www.alkemlabs.com/policies/privacy-policy)

Data Breaches: 0 instances

Assurance and Compliance

Assured Indicators: Select essential indicators assured by Deloitte Haskins & Sells LLP

Board Oversight: CSR and Sustainability Committee responsible for sustainability decision-making

Highest Authority: Mr. Sandeep Singh (Managing Director) responsible for implementation and oversight

Review Frequency: Quarterly/need-based reviews of performance and compliance